AppointmentsUK Cannabis Firm Appoints New CEO Following Tobacco Giant’s...

UK Cannabis Firm Appoints New CEO Following Tobacco Giant’s Swoop For Canadian LP


CANNABIS investment company Greencare Capital has appointed Richard Tonthat as CEO just weeks after his work with British American Tobacco on its £125m equity stake in Canada’s Organigram.

Mr Tonthat, 37, qualified as a Chartered Accountant with PricewaterhouseCoopers and is an experienced corporate financier and investment adviser. 

Prior to joining Greencare, he was an independent consultant advising on M&A, debt financing and equity investments. During this time, he worked with British American Tobacco plc on a number of transactions, including the recent C$221m equity investment into Organigram.

Richard Tonthat

Previously he was a Director in the Corporate Finance team at Grant Thornton where he managed a portfolio of public company clients and had a proven track record of delivering multiple M&A, IPO, debt and private equity fundraising projects.

Nicholas Lee, Greencare’s Non-executive Chairman, said: “I am pleased to welcome Richard to the Greencare Board. His transaction experience and investment advisory background, combined with direct experience of the international cannabis market will be of great benefit to the company as we continue to build our investment portfolio.”

Greencare Capital plc is quoted on the Aquis Stock Exchange Growth Market. The Company was incorporated on October 1, 2019, and was admitted to the exchgange on December 30, 2019.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you